Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes (Q46829066)

25 December 2017

title

Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes (English)

1 reference

25 December 2017

0 references

1 reference

Mark A Yorek

6

0 references

author name string

Christine L Oltman

1

1 reference

25 December 2017

Travis L Kleinschmidt

2

1 reference

25 December 2017

Eric P Davidson

3

1 reference

25 December 2017

Lawrence J Coppey

4

1 reference

25 December 2017

Donald D Lund

5

1 reference

25 December 2017

publication date

29 November 2007

1 reference

25 December 2017

published in

Vascular Pharmacology

1 reference

25 December 2017

volume

48

1 reference

25 December 2017

issue

1

1 reference

25 December 2017

page(s)

47-53

1 reference

25 December 2017

Exercise enhances vasorelaxation in experimental obesity associated hypertension.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

PPARγ activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Slowing of motor nerve conduction velocity in streptozotocin-induced diabetic rats is preceded by impaired vasodilation in arterioles that overlie the sciatic nerve

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD(P)H oxidase-dependent superoxide production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Restoration of coronary endothelial function in obese Zucker rats by a low-carbohydrate diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Oxidant stress-induced increase in myogenic activation of skeletal muscle resistance arteries in obese Zucker rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Impaired insulin-induced vasodilation in small coronary arteries of Zucker obese rats is mediated by reactive oxygen species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Upregulation of Endothelial Nitric Oxide Synthase by HMG CoA Reductase Inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Rosuvastatin treatment reverses impaired coronary artery vasodilation in fructose-fed, insulin-resistant rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Reactive oxygen species mediate arachidonic acid-induced dilation in porcine coronary microvessels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Progression of vascular and neural dysfunction in sciatic nerves of Zucker diabetic fatty and Zucker rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Progression of coronary and mesenteric vascular dysfunction in Zucker obese and Zucker diabetic fatty rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Vascular and neural dysfunction in Zucker diabetic fatty rats: a difficult condition to reverse.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Attenuation of vascular/neural dysfunction in Zucker rats treated with enalapril or rosuvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Oxidant stress and constrictor reactivity impair cerebral artery dilation in obese Zucker rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Impact of obesity on coronary microvascular function in the Zucker rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Diagnosis, prevention, and intervention for the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Evidence for contribution of vascular NAD(P)H oxidase to increased oxidative stress in animal models of diabetes and obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Recommendations for special populations: diabetes mellitus and the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Augmented adrenergic vasoconstriction in hypertensive diabetic obese Zucker rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Enalapril Prevents Impaired Nitric Oxide Synthase–Dependent Dilatation of Cerebral Arterioles in Diabetic Rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

Ramipril and the development of diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.11.005

10.1016/J.VPH.2007.11.005

7 January 2021

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017